Zurück zu Projekte

16001.1;9 PFLS-LS

Optimization for a novel therapy targeting bacterial toxins in severe infections

Zusammenfassung

Optimization for a novel therapy targeting bacterial toxins in severe infections

Weitere Texte

Abstract

CAL02 is a non-antibiotic drug for severe bacterial infections that targets toxins and whose potency has been demonstrated in vitro and in vivo against various toxins and relevant bacterial strains. CAL02 has now been manufactured according to a new process optimized for GMP production and up-scaling. The proposed project?s objective is to optimize in vitro experiments for the validation of the GMP-enabled batch and provide key answers in order to get regulatory Scientific Advice with a view to launching a first clinical trial.

Beteiligte

Annette Draeger

Kontaktperson

draeger@ana.unibe.ch

Universität Bern Annette Draeger Baltzerstr. 2 3012 Bern BE CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2014-03-31
Enddatum
2015-06-30
Bewilligte Gesamtkosten
CHF 73414.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Nicht aufteilbare / nicht zuteilbare Forschung

Forschungsdisziplinen

  • T490 Biotechnology 100.0%